Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
alpha-galactosylceramide
- Development stage
- Phase 2
- Lead developer
- Kyowa Kirin
- Modality
- Small Molecules
- Administration
- Intravenous, Intranasal, Subcutaneous, Intramuscular
01
Overview
Alpha-galactosylceramide is a synthetic glycolipid originally derived as an analogue of agelasphin-9b from marine sponges. It acts as a potent immunostimulant by activating natural killer T (NKT) cells through presentation by CD1d molecules on antigen-presenting cells, leading to the activation and expansion of NKT cells. This activation results in downstream immune effects, including dendritic cell maturation and B-cell activation via IL-4 production. Alpha-galactosylceramide has demonstrated antitumor activity in animal models and has been investigated as an adjuvant for vaccines and for its potential to induce T-cell immunity against cancer and viral infections[1][2][3][5][6]. Development efforts have included use in hepatitis B, hepatitis C, lung cancer, and as a mucosal vaccine adjuvant.
- Other names
- alpha-galactosylceramideα-GalCeragelasphin-9b (synthetic analogue)
02
Targets
iNKT TCR (Invariant natural killer T-cell receptor)CD1D (Tumor-associated macrophage/myeloid-derived suppressor cell CD1d complex)
Beyond the preview
Go deeper on alpha-galactosylceramide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on alpha-galactosylceramide.